Combination

Horizon Aircraft Secures Investment from Canso Investment Counsel Ltd.

Retrieved on: 
Tuesday, December 5, 2023
Aircraft, Business analyst, Vertical, CAD, Combination, Growth, Aviation, History, Risk management

TORONTO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Robinson Aircraft Ltd., a hybrid electric Vertical TakeOff and Landing (“eVTOL”) aircraft developer (“Horizon Aircraft”), today announced a strategic investment in the form of a convertible note purchased by certain accounts of Canso Investment Counsel Ltd. (“Canso”) and affiliated companies for an aggregate $6.7 million CAD.

Key Points: 
  • TORONTO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Robinson Aircraft Ltd., a hybrid electric Vertical TakeOff and Landing (“eVTOL”) aircraft developer (“Horizon Aircraft”), today announced a strategic investment in the form of a convertible note purchased by certain accounts of Canso Investment Counsel Ltd. (“Canso”) and affiliated companies for an aggregate $6.7 million CAD.
  • Brandon Robinson, Chief Executive Officer and Co-Founder of Horizon Aircraft commented, “Canso has a strong history of supporting the growth of numerous businesses across Canada since its inception.
  • Canso is an experienced investor in aviation and space technology and is a champion of Canadian aerospace companies in particular.
  • Horizon Aircraft believes that Canso’s support with this financing will strengthen Horizon’s position as a leader in the eVTOL market and accelerate our developmental timeline.

Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Initial Business Combination to January 3, 2024

Retrieved on: 
Monday, December 4, 2023
Acquisition, VSAC, Extension, Combination, Exercise

MIAMI, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”), a special purpose acquisition company, announced today that on November 30, 2023, its sponsor, Vision Sensing, LLC, deposited $60,000 into the Company’s trust account, which is the sum that the Company must pay to extend the date by which the Company must consummate its initial business combination from December 3, 2023, to January 3, 2024 (the “Extension”).

Key Points: 
  • MIAMI, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”), a special purpose acquisition company, announced today that on November 30, 2023, its sponsor, Vision Sensing, LLC, deposited $60,000 into the Company’s trust account, which is the sum that the Company must pay to extend the date by which the Company must consummate its initial business combination from December 3, 2023, to January 3, 2024 (the “Extension”).
  • The Company has issued to its sponsor a non-interest bearing, unsecured promissory note in the principal amount of $60,000 as consideration for the funding.
  • This is the second of up to six one-month extensions that the Company is authorized to obtain under its amended and restated certificate of incorporation as recently amended on October 25, 2023.
  • The combined company’s common stock is expected to trade on the Nasdaq Capital Market under the ticker symbol “NSIM”.

Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial

Retrieved on: 
Friday, December 1, 2023
Hebrew University of Jerusalem, Blood, MEAI, Depression, TEL, Mouse, CWY, Combination, Animal, Appetite, Obesity, PEA, Central nervous system, Carbon, Safety, Therapy, Disorder, Pharmaceutical industry

TEL AVIV, Israel, Dec. 01, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced earlier this week successful results from a pre-clinical trial performed by Professor Joseph Tam from The Hebrew University of Jerusalem.

Key Points: 
  • The administered treatment exhibited a meaningful degree of tolerance, leaving the viability of the mice unaffected across all experimental groups.
  • A notable reduction in food consumption (appetite) and meal sizes was also observed, primarily at 40 and 20 mg/kg of MEAI.
  • "I am encouraged by the positive results from our recent pre-clinical trial, which represent another milestone in our ongoing efforts to develop safe and effective innovative therapies.
  • "The trial's findings, including increased metabolic activity, reduced appetite, and enhanced fat oxidation, are promising indicators of the treatment's efficacy and safety."

Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to January 3, 2024

Retrieved on: 
Thursday, November 30, 2023
Transfer, Acquisition, VSAC, Extension, Combination, Exercise, Security (finance)

MIAMI, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced today that it has notified Continental Stock Transfer & Trust Company that it intends to extend the date by which the Company must consummate its initial business combination from December 3, 2023, to January 3, 2024, and that its sponsor, Vision Sensing, LLC, intends to deposit into the Company’s trust account an aggregate of $60,000 by December 4, 2023 (the “Extension”).

Key Points: 
  • MIAMI, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced today that it has notified Continental Stock Transfer & Trust Company that it intends to extend the date by which the Company must consummate its initial business combination from December 3, 2023, to January 3, 2024, and that its sponsor, Vision Sensing, LLC, intends to deposit into the Company’s trust account an aggregate of $60,000 by December 4, 2023 (the “Extension”).
  • In connection with the Extension, the Company intends to issue to its sponsor a non-interest bearing, unsecured promissory note in the principal amount of $60,000 as consideration for the funding.
  • This will be the second of up to six one-month extensions that the Company is authorized to obtain under its amended and restated certificate of incorporation as recently amended on October 25, 2023.
  • The combined company’s common stock is expected to trade on the Nasdaq Capital Market under the ticker symbol “NSIM”.

ClimateRock Announces Termination of Business Combination Agreement

Retrieved on: 
Thursday, November 30, 2023
Combination, Business analyst, Termination, CLRC

that the Company has elected to terminate the Amended and Restated Business Combination Agreement among the Company, E.E.W.

Key Points: 
  • that the Company has elected to terminate the Amended and Restated Business Combination Agreement among the Company, E.E.W.
  • and the other parties thereto, dated as of August 3, 2023 (the “Business Combination Agreement”), effective immediately, pursuant to Section 9.1(b) and 9.2 thereof, since the conditions to the closing of the initial business combination were not satisfied or waived by the outside date of September 30, 2023 (the “Termination”).
  • As a result, the Business Combination Agreement is of no further force and effect, except for certain specified provisions in the Business Combination Agreement, which shall survive the Termination and remain in full force and effect in accordance with their respective terms.
  • The Company and its sponsor intend to seek alternative ways to consummate an initial business combination.

Fenix 360 Pte Ltd. To Go Public Through Merger With DUET Acquisition Corp. to Create a Global Social Media Platform

Retrieved on: 
Tuesday, November 28, 2023
Social media, Acquisition, Transaction, DUET, Combination

NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Fenix 360 Pte Ltd (“FENIX360”), a global social media company incorporated in Singapore that is designed to provide artists and creators with enhanced compensation, tools and control, and DUET Acquisition Corp. (NASDAQ: DUET) (“DUET”), a special purpose acquisition company incorporated in Delaware, announced today that that they have entered into a business combination agreement (the “Business Combination Agreement”), pursuant to which DUET will acquire 100% of the outstanding equity interests of FENIX360 (the “Transaction”).

Key Points: 
  • NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Fenix 360 Pte Ltd (“FENIX360”), a global social media company incorporated in Singapore that is designed to provide artists and creators with enhanced compensation, tools and control, and DUET Acquisition Corp. (NASDAQ: DUET) (“DUET”), a special purpose acquisition company incorporated in Delaware, announced today that that they have entered into a business combination agreement (the “Business Combination Agreement”), pursuant to which DUET will acquire 100% of the outstanding equity interests of FENIX360 (the “Transaction”).
  • The Transaction is expected to be completed in the first half of 2024, subject to regulatory approvals and other customary closing conditions.
  • The Transaction values FENIX360 at a $610 million enterprise value.

SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment

Retrieved on: 
Tuesday, November 28, 2023
Hebrew University of Jerusalem, Blood, MEAI, Depression, TEL, CWY, Combination, Animal, Appetite, Obesity, PEA, Central nervous system, Carbon, Safety, Therapy, Disorder, Pharmaceutical industry

TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced successful results from a pre-clinical trial performed by Professor Joseph Tam from The Hebrew University of Jerusalem.

Key Points: 
  • The combination treatment includes palmitoylethanolamide (PEA), an anti-inflammatory agent and the active ingredient of the Company’s proprietary CannAmide™, and MEAI, Clearmind’s novel proprietary psychedelic treatment for various addictions, obesity, and depression (the “Combination Treatment”).
  • The administered treatment exhibited a meaningful degree of tolerance, leaving the mice's viability unaffected across all experimental groups.
  • The changed rates of oxygen consumption and carbon dioxide emission indicate increases in the metabolic process and fat burn.
  • "The trial's findings, including increased metabolic activity, reduced appetite, and enhanced fat oxidation, are promising indicators of the treatment's efficacy and safety."

Veea to Become Publicly Traded Company via proposed Business Combination with Plum Acquisition Corp. I

Retrieved on: 
Tuesday, November 28, 2023
Cloud, APS, Wi-Fi, Digital, Cayman Islands, Party, Business analyst, Business, Acquisition, LLP, Digital inclusion, Wireless, Combined, FWA, SAN, Internet of things, Privacy, Internet, Point, IP, Engineering, Combination, HSR, Security (finance)

NEW YORK, NY and SAN FRANCISCO, CA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Veea Inc. (“Veea” or the “Company”), a digital transformation company, and Plum Acquisition Corp.

Key Points: 
  • NEW YORK, NY and SAN FRANCISCO, CA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Veea Inc. (“Veea” or the “Company”), a digital transformation company, and Plum Acquisition Corp.
  • I (“Plum”, and together, the “Parties”) (Nasdaq: PLMI), a Cayman Islands exempted company formed as a special purpose acquisition company by Ursula Burns, Kanishka Roy and Mike Dinsdale, today announced their entry into a definitive business combination agreement (the “Business Combination Agreement”) related to a proposed merger (such merger and related transactions, including the issuance by Plum of securities in connection therewith, collectively, the “Business Combination”) expected to result in Veea becoming a publicly traded company (referred to herein as the “Combined Company” ) whose business, after the closing (the “Closing”), assuming the occurrence thereof, will be the continued business of Veea.
  • Proceeds from the proposed Business Combination and financing transactions are expected to support the Combined Company in its business plans, including Veea’s mission of positioning itself as a leader of Digital Inclusion across the globe.
  • The proposed Business Combination has, prior to the execution of the Business Combination Agreement, been approved by the boards of directors of each of Veea and Plum.

Investcorp Europe Acquisition Corp I and OpSec Group Secure Investment from SAKATA INX

Retrieved on: 
Tuesday, December 19, 2023
Professional Services, Security, Technology, Manufacturing, Software, Finance, Other Manufacturing, Partnership, Multimedia, Acquisition, Operations security, Combination, Security (finance)

OpSec Group (“OpSec”), a global leader in IP management and brand protection solutions, and Investcorp Europe Acquisition Corp I (Nasdaq: IVCB) (“Investcorp Europe”), a special purpose acquisition company, today announced a strategic investment from SAKATA INX Corporation (“SAKATA INX”) in the form of unsecured convertible loan notes issued by OpSec (the “Loan Notes“).

Key Points: 
  • OpSec Group (“OpSec”), a global leader in IP management and brand protection solutions, and Investcorp Europe Acquisition Corp I (Nasdaq: IVCB) (“Investcorp Europe”), a special purpose acquisition company, today announced a strategic investment from SAKATA INX Corporation (“SAKATA INX”) in the form of unsecured convertible loan notes issued by OpSec (the “Loan Notes“).
  • View the full release here: https://www.businesswire.com/news/home/20231218541040/en/
    As previously announced, on April 25, 2023, OpSec and Investcorp Europe entered into a definitive business combination agreement (the “Business Combination Agreement”) that would result in OpSec becoming a public company.
  • Upon closing of the proposed business combination, the newly combined company will operate as OpSec Group and will trade under the symbol “OPSC” on Nasdaq.
  • Selva Selvaratnam, CEO of OpSec, said: “We are excited to further solidify our strategic alliance with SAKATA INX and truly appreciate their partnership and investment in support of our public listing.

Bedrock Bioscience Announces Groundbreaking Medical Study Published in Prestigious Journal

Retrieved on: 
Thursday, December 21, 2023
Quality of life, Peripheral neuropathy, Research, Health, Platelet-rich plasma, Extracorporeal shockwave therapy, Medicine, University, Scientific Research Publishing, Molecular medicine, Combination, Patient, Canadian International Council, History, Oil lamp, Pharmaceutical industry

CLEARWATER, Fla., Dec. 20, 2023 /PRNewswire/ -- Bedrock Bioscience is thrilled to announce the publication of a groundbreaking medical study in the esteemed International Journal of Clinical Medicine.

Key Points: 
  • CLEARWATER, Fla., Dec. 20, 2023 /PRNewswire/ -- Bedrock Bioscience is thrilled to announce the publication of a groundbreaking medical study in the esteemed International Journal of Clinical Medicine.
  • This study marks a significant milestone in the field of Peripheral Neuropathy and reaffirms Bedrock's commitment to advancing medical knowledge and improving patient care.
  • Bedrock Bioscience is known for its commitment to scientific excellence and has a history of pioneering medical breakthroughs.
  • For more information about Bedrock Bioscience and its groundbreaking medical study, please visit www.bedrockbioscience.com/research or contact its media relations department at [email protected] .